Imutrex 7.5

Imutrex (Methotrexate) 7.5mg Tablets is a medication used to treat various conditions, including:

• Rheumatoid arthritis (RA)
• Psoriatic arthritis (PsA)
• Juvenile idiopathic arthritis (JIA)
• Severe psoriasis
• Osteosarcoma
• Gestational choriocarcinoma

Composition: Each tablet of Imutrex contains 7.5mg of Methotrexate (an active pharmaceutical ingredient).

Mechanism of Action: Methotrexate works by inhibiting the enzyme dihydrofolate reductase, which is necessary for the production of tetrahydrofolate. This leads to a decrease in the production of purines and pyrimidines, which are building blocks of DNA and RNA. This results in inhibition of cell proliferation and division, making it an effective treatment for various conditions.

Dosage: The recommended dose of Imutrex varies depending on the condition being treated. For rheumatoid arthritis and psoriatic arthritis, the usual dose is 7.5-20mg taken orally once a week. For severe psoriasis, the usual dose is 10-25mg taken orally once a week. For osteosarcoma, the usual dose is 20-30mg/m² taken orally once a week.

Side Effects: Common side effects of Imutrex include:

• Nausea
• Vomiting
• Diarrhea
• Stomach pain
• Fatigue
• Headache
• Dizziness
• Rash

Rare but serious side effects include:

• Increased risk of infections, including serious infections such as pneumonia, sepsis, and opportunistic infections
• Increased risk of liver damage, including hepatitis and liver failure
• Increased risk of bone marrow suppression, including anemia, neutropenia, and thrombocytopenia
• Increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis

Recommendation: Imutrex is recommended for patients with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, severe psoriasis, osteosarcoma, or gestational choriocarcinoma. Patients with a history of hypersensitivity reactions to Methotrexate or other immunosuppressive agents should not receive Imutrex.

Important Note:

• Imutrex should be used under the guidance of a healthcare provider with experience in the treatment of the condition being treated.
• Patients with a history of liver disease, kidney disease, or blood disorders should be closely monitored while taking Imutrex.
• Imutrex may interact with other medications, such as antibiotics, anticonvulsants, and sulfa-based medications. Patients should inform their healthcare provider of all medications they are taking before starting Imutrex therapy.
• Patients should be advised to report any symptoms of hypersensitivity reactions, such as rash, itching, swelling, or difficulty breathing.